Crinetics Pharmaceuticals, Inc. (CRNX)
| Market Cap | 9.01B +208.7% |
| Revenue (ttm) | 42.16M +2,928.4% |
| Net Income | -501.61M |
| EPS | -5.03 |
| Shares Out | 106.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,208,422 |
| Open | 84.96 |
| Previous Close | n/a |
| Day's Range | 84.92 - 85.01 |
| 52-Week Range | 31.00 - 85.01 |
| Beta | 0.09 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About CRNX
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candida... [Read more]
Financial Performance
In 2025, Crinetics Pharmaceuticals's revenue was $7.70 million, an increase of 640.71% compared to the previous year's $1.04 million. Losses were -$465.32 million, 55.9% more than in 2024.
Financial StatementsNews
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pha...
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired
Crinetics Pharmaceuticals Earnings release: Q2 2026
Crinetics Pharmaceuticals released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Crinetics Pharmaceuticals Quarterly report: Q2 2026
Crinetics Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 3, 2026.
Crinetics Pharmaceuticals Proxy statement: Proxy filing
Crinetics Pharmaceuticals filed a proxy statement on July 31, 2026, providing details for shareholder voting and corporate governance matters.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Crinetics Pharmaceuticals Proxy statement: Proxy filing
Crinetics Pharmaceuticals filed a proxy statement on July 21, 2026, providing details for shareholder voting and corporate governance matters.
Crinetics Pharmaceuticals Slides: Corporate presentation
Crinetics Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2026.
Crinetics Pharmaceuticals Proxy statement: Proxy filing
Crinetics Pharmaceuticals filed a proxy statement on July 10, 2026, providing details for shareholder voting and corporate governance matters.
How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks
More mergers among brand-name consumer companies seem likely—following a record $2.6 trillion worth of transactions announced in the first half of 2026.
Crinetics shares surge after Vertex agrees to $10B cash buyout
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-...
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - July 7, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Crinetics Pharmaceutica...
This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal
Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.
Samsung, Micron, Rivian, SpaceX, Crinetics, and More Stocks That Explain Today's Market
AI stocks take a beating, with South Korean memory-chip maker Samsung Electronics setting the tone for the broader market.
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
The acquisition would add to Vertex's pipeline and potentially grow its annual revenue by $5 billion with the addition of Crinetics-developed drugs Palsonify and Atumelnant, the company said.
Vertex to buy Crinetics in $10 billion deal
Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity value of about $10 billion, the companies said on Monday.
Vertex to Acquire Crinetics Pharmaceuticals
BOSTON & SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, de...
Crinetics Pharmaceuticals Proxy statement: Proxy filing
Crinetics Pharmaceuticals filed a proxy statement on July 6, 2026, providing details for shareholder voting and corporate governance matters.
Crinetics Pharmaceuticals Proxy statement: Proxy filing
Crinetics Pharmaceuticals filed a proxy statement on July 6, 2026, providing details for shareholder voting and corporate governance matters.
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after t...
Crinetics Pharmaceuticals Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation approval. All proposals passed, and no questions were raised by stockholders during the Q&A session.
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities
Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions
Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taki...